Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Leach

Showing results (101-110 of 127) with videos related to

Pageof 13
Sort By:
Advances in Therapy|September 3, 2016
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade<sup>®</sup> (Infliximab)Mazin Derzi, Theodore R Johnson, Ahmed M Shoieb, et al.
Journal of Toxicologic Pathology|March 15, 2016
Nonproliferative and Proliferative Lesions of the Gastrointestinal Tract, Pancreas and Salivary Glands of the Rat and MouseThomas Nolte, Patricia Brander-Weber, Charles Dangler, et al.
Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons|August 19, 2009
Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patientsVivek Thumbigere-Math, Ma'ann C Sabino, Rajaram Gopalakrishnan, et al.
Disability and Health Journal|December 3, 2022
Recommendations to improve the patient experience and avoid bias when prenatal screening/testingStephanie Meredith, Scotti Brackett, Keith M Diaz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 13, 2011
Cytosolic phospholipase A2α blockade abrogates disease during the tissue-damage effector phase of experimental autoimmune encephalomyelitis by its action on APCsParesh Thakker, Suzana Marusic, Nancy L Stedman, et al.
Mabs|February 9, 2016
Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challengesKathryn Chapman, Akosua Adjei, Paul Baldrick, et al.
Clinical Pharmacology and Therapeutics|August 7, 2020
Strategies and Recommendations for Using a Data-Driven and Risk-Based Approach in the Selection of First-in-Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) AssessmentMichael W Leach, David O Clarke, Sherri Dudal, et al.
Immunity|January 5, 2002
IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivoM M Fort, J Cheung, D Yen, et al.
Gynecologic Oncology|July 15, 2014
A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancerIgnace Vergote, Russell J Schilder, Charles H Pippitt, et al.
Cell Reports|July 9, 2013
Facilitates chromatin transcription complex is an "accelerator" of tumor transformation and potential marker and target of aggressive cancersHenry Garcia, Jeffrey C Miecznikowski, Alfiya Safina, et al.
Pageof 13

Showing results (101-110 of 127) with videos related to

Sort By:
Pageof 13
Advances in Therapy|September 3, 2016
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade<sup>®</sup> (Infliximab)Mazin Derzi, Theodore R Johnson, Ahmed M Shoieb, et al.
Journal of Toxicologic Pathology|March 15, 2016
Nonproliferative and Proliferative Lesions of the Gastrointestinal Tract, Pancreas and Salivary Glands of the Rat and MouseThomas Nolte, Patricia Brander-Weber, Charles Dangler, et al.
Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons|August 19, 2009
Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patientsVivek Thumbigere-Math, Ma'ann C Sabino, Rajaram Gopalakrishnan, et al.
Disability and Health Journal|December 3, 2022
Recommendations to improve the patient experience and avoid bias when prenatal screening/testingStephanie Meredith, Scotti Brackett, Keith M Diaz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 13, 2011
Cytosolic phospholipase A2α blockade abrogates disease during the tissue-damage effector phase of experimental autoimmune encephalomyelitis by its action on APCsParesh Thakker, Suzana Marusic, Nancy L Stedman, et al.
Mabs|February 9, 2016
Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challengesKathryn Chapman, Akosua Adjei, Paul Baldrick, et al.
Clinical Pharmacology and Therapeutics|August 7, 2020
Strategies and Recommendations for Using a Data-Driven and Risk-Based Approach in the Selection of First-in-Human Starting Dose: An International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) AssessmentMichael W Leach, David O Clarke, Sherri Dudal, et al.
Immunity|January 5, 2002
IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivoM M Fort, J Cheung, D Yen, et al.
Gynecologic Oncology|July 15, 2014
A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancerIgnace Vergote, Russell J Schilder, Charles H Pippitt, et al.
Cell Reports|July 9, 2013
Facilitates chromatin transcription complex is an "accelerator" of tumor transformation and potential marker and target of aggressive cancersHenry Garcia, Jeffrey C Miecznikowski, Alfiya Safina, et al.
Pageof 13